Interplay of atherogenic factors, protein intake and betatrophin levels in obese–metabolic syndrome patients treated with hypocaloric diets by Crujeiras, A.B. (Ana B.) et al.
1 
 
Interplay of atherogenic factors, protein intake and betatrophin levels in obese-1 
metabolic syndrome patients treated with hypocaloric diets 2 
Ana B. Crujeiras 1,3, Maria A Zulet 2,3, Itziar Abete 2,3, María Amil 1,3, Marcos C 3 
Carreira 1,3, J Alfredo Martínez 2,3, Felipe F Casanueva 1,3 4 
1Laboratory of Molecular and Cellular Endocrinology, Instituto de Investigación 5 
Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS) and 6 
Santiago de Compostela University (USC), Santiago de Compostela, Spain; 2Dpt. 7 
Nutrition, Food Sciences and Physiology, University of Navarra (UNAV), Pamplona, 8 
Spain; 3 CIBER Fisiopatología de la Obesidad y la Nutrición (CIBERobn), Madrid, 9 
Spain. 10 
Running title: Betatrophin and hypocaloric diets in obesity 11 
Conflict of interest statement: The authors declare no conflict of interest. 12 
Correspondence:  13 
Dr. Ana B. Crujeiras. Molecular and Cellular Endocrinology Area (Lab. 2). Instituto de 14 
Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago 15 
(CHUS). C/ Choupana, s/n. 15706 Santiago de Compostela. Spain. E-mail: 16 
anabelencrujeiras@hotmail.com; Tel: +34 981955069; Fax: +34 981 956189. Prof. J. 17 
Alfredo Martínez. Department of Nutrition, Food Science and Physiology, University of 18 
Navarra. C/Irunlarrea 1, Pamplona 31008, Spain. E-mail: jalfmtz@unav.es; Tel.: +34 19 
948425600, ext. 806424; fax: +34 948425649 20 
 21 
 22 
2 
 
ABSTRACT 23 
CONTEXT. The understanding of the potential role of betatrophin in human metabolic 24 
disorders is a current challenge.  25 
OBJECTIVE. The present research evaluated circulating betatrophin levels in obese 26 
patients with metabolic syndrome features under energy-restricted weight-loss programs 27 
and in normal weight in order to stablish the putative interplay between the levels of this 28 
hormone, diet and metabolic risk factors linked to obesity and associated comorbidities. 29 
SUBJECTS AND METHODS: One-hundred and forty three participants were 30 
enrolled in the study (95 obese-metabolic syndrome; age 49.5±9.4 y.o; BMI 35.7±4.5 31 
kg/m2 / 48 normal-weight; age 35.71±8.8 y.o; BMI 22.9±2.2 kg/m2). A nutritional 32 
therapy consisting in two hypocaloric strategies (Control diet based on the AHA 33 
recommendations and the RESMENA diet, a novel dietary program with changes in the 34 
macronutrient distribution) was only prescribed to obese-metabolic syndrome 35 
participants who were randomly allocated to the dietary strategies. Dietary records, 36 
anthropometrical and biochemical variables as well as betatrophin levels were analysed 37 
before (pre-intervention, wk 0), at 8 weeks (post-intervention, wk 8) and after 4 38 
additional months of self-control period (follow-up, wk 24)  39 
RESULTS. Betatrophin levels were higher in obese-metabolic syndrome patients than 40 
normal-weight subjects (1.24±0.43 ng/mL vs. 0.97±0.69 ng/mL, respectively, p=0.012), 41 
and levels were positively associated with body composition, metabolic parameters, 42 
leptin and irisin in all participants at baseline. Notably, low pre-intervention (wk0) 43 
betatrophin levels in obese patients were significantly associated with higher dietary-44 
induced changes in atherogenic risk factors after 8 weeks. Moreover, protein intake, 45 
especially proteins from animal sources, was an independent determinant of betatrophin 46 
levels after dietary treatment (B=-0.27; p=0.012).  47 
CONCLUSIONS. Betatrophin is elevated in obese patients with metabolic syndrome 48 
features and is associated with poorer nutritional outcomes of adiposity and 49 
dyslipidemia traits after a weight-loss program. Dietary protein intake could be a 50 
relevant modulator of betatrophin secretion and activity.  51 
 52 
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INTRODUCTION 54 
Obesity is a worldwide health problem, and it is a worldwide epidemic at present [1]. 55 
The prevalence of obesity is increasing rapidly in most countries, and it is a major 56 
driving force for the increased development of dyslipidemia and glucose intolerance [2]. 57 
These metabolic disorder commonly associated with an excess of adiposity consist of a 58 
cluster of features that are included in the metabolic syndrome (MetSyn) which often 59 
results in atherosclerosis, cardiovascular diseases, and diabetes [3]. 60 
The design of an integral treatment for patients with obesity/metabolic syndrome 61 
has been an elusive task until now. The contradiction of facing an universal epidemic 62 
without effective treatments likely reflects our lack of an adequate understanding of the 63 
foundations of obesity [4]. Greater insight into the mechanisms of energy and body 64 
weight homeostasis will translate into better knowledge for the treatment of the 65 
obese/metabolic syndrome patients, being important to investigate the underlying 66 
mechanism involved in the obesity comorbidities and at the same time to find 67 
interactions with the diet in order to offer a better holistic therapy for this syndrome [5]. 68 
The discovery of leptin secretion by the adipose tissue opened a new era in this 69 
quest for new insights in the basis of obesity [6]. The age of leptin primarily 70 
demonstrated the relevance of peripheral tissues, such as fat, in the regulation of 71 
metabolism and this view was endorsed by subsequent discoveries in other tissues such 72 
as gastric [7, 8] and distal intestine [9]. Considerable evidence emerged in the last 73 
several years, which suggests that muscle and muscle contraction during exercise may 74 
have regulatory activity on the overall metabolism by the secretion of other factors, such 75 
as irisin [10]. In this context, the findings of the role of betatrophin, which promotes 76 
pancreatic B-cell expansion and insulin secretion and improves glucose tolerance in 77 
mice [11], and  the findings of three other independent groups that characterized this 78 
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novel nutritionally regulated factor that is secreted by liver and adipose tissue [11-17] 79 
created high expectations to our understanding and ability to counteract dyslipidemia 80 
and hyperglycemia. The emerging importance of betatrophin as a critical regulator of 81 
metabolic pathways in preclinical models prompted rapid studies in humans to evaluate 82 
the potential translation of findings in mice to the clinic. However, a relevant 83 
controversy soon evidenced because some authors reported increased circulating levels 84 
of betatrophin in type 2 diabetes and obesity (T2DM) [12, 18-22], but other authors 85 
found no differences [23, 24] or a decrease in circulating levels of betatrophin under 86 
these metabolic impairments [25]. These results challenged the potential role of 87 
betatrophin as a therapeutic target in metabolic disorders. Further studies of variations 88 
in circulating levels of betatrophin under a therapeutic weight loss program have not 89 
been elucidated previously, and these results could shed light on these controversial 90 
outcomes.  91 
The aim of present study was to evaluate circulating betatrophin levels in obese 92 
patients with metabolic syndrome features under energy-restricted weight-loss programs 93 
and in normal weight in order to establish interplay between the levels of this hormone, 94 
diet and metabolic risk factors linked to obesity and associated comorbidities. Thus, it 95 
was examined (1) the differences in betatrophin levels between normal weight and 96 
obese patients and its association with metabolic risk factors; (2) the association 97 
between baseline betatrophin levels and the response to an energy restriction treatment 98 
in obese patients on body composition and glucose and lipid metabolic factors; (3) the 99 
time-course of betatrophin levels after a dietary treatment with different protein content 100 
on betatrophin levels. 101 
 102 
 103 
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SUBJECTS AND METHODS 104 
Subjects 105 
A total of 143 subjects were enrolled in this study. A group of 95 obese patients 106 
(50 men, 44 women), 49.5±9.4 years old with a body mass index (BMI) of 35.7±4.5 107 
kg/m2 who were interested in following a weight-loss program were recruited to 108 
participate in the study through local advertisements. Forty-eight normal-weight 109 
subjects (16 men, 32 women), 35.71±8.8 years old with a BMI of 22.9±2.2 kg/m2 were 110 
enrolled as controls. All participants provided a medical history, physical examination, 111 
and routine laboratory tests. Normal-weight patients (BMI≤25 kg/m2) reported no 112 
history of diabetes mellitus, high blood pressure (BP), or dyslipidemia and were healthy 113 
overall. Obese patients (BMI>25 kg/m2) presented at least two of the International 114 
Diabetes Federation (IDF) criteria for metabolic syndrome (MetSyn) [26]. Some of the 115 
metabolic syndrome patients (23 %) included in this study were diagnosed for T2DM 116 
and they were on antidiabetic medication at the baseline visit. Moreover, 62% of 117 
metabolic syndrome patients showed insulin resistance according to the cutoff point of 118 
an HOMA>2.5. Exclusion criteria for study enrollment were pregnancy, alcohol or drug 119 
abuse and chronic prescriptions of other medical drugs different of antidiabetic 120 
medication.  121 
Written informed consent to participate in the trial was obtained before the start 122 
of the study in agreement with the Helsinki Declaration and followed national and 123 
European Union guidelines. The protocol for this study was approved by the Clinica 124 
Universidad de Navarra Ethics Committee (065/2009) and appropriately registered al 125 
Clinical Trials.gov (NCT01087086).  126 
 127 
 128 
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Nutritional therapy program for weight loss  129 
Obese patients followed a therapy program based on a nutritional intervention 130 
that was controlled by trained dieticians from the Department of Nutrition, Food 131 
Sciences and Physiology of the University of Navarra. Participants followed a therapy 132 
program based on the RESMENA-S (MEtabolic Syndrome REduction in Navarra) 133 
study, which was a randomized controlled intervention trial to improve clinical criteria 134 
and biomarkers associated with MetSyn using a dietary strategy for weight loss [27, 28]. 135 
The six-month study was performed in two sequential periods: one eight-week 136 
intervention period (intervention period) in which subjects received nutritional 137 
assessments every 15 days and a 4-month self-control period in which subjects followed 138 
the habits learned in the first period (Follow-up period). Two energy-restricted diets 139 
were prescribed and compared. A 30% energy restriction was applied to the total energy 140 
requirements of each patient. The Control diet was based on AHA guidelines and 141 
included 3-5 meals/day and a macronutrient distribution of 50-55% total caloric value 142 
from carbohydrates, 15% from proteins and 30% from lipids. The RESMENA diet was 143 
composed of 7 meals/day with a 40% total caloric value from carbohydrates, 30% from 144 
proteins and 30% from lipids. Anthropometrical, biochemical, and dietary intake 145 
variables were assessed at baseline (wk 0), after the intervention period (wk 8) and at 146 
the end of the study (wk 24). Dietary compliance was obtained through 48-hour 147 
weighed food records [27, 28], and diet composition was analyzed using the DIAL 148 
software (Alce Ingenieria, Madrid, Spain). 149 
 150 
Anthropometrical and body composition measurements 151 
Body weight measurements were performed using a digital balance that was 152 
accurate to 0.1 kg (Seca 767; Vogel & Halke, Germany), and height was measured 153 
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using a wall-mounted stadiometer (Seca 220; Vogel &Halke). Waist circumference was 154 
measured at the site of the smallest circumference between the rib cage and the iliac 155 
crest. Body composition was measured using bioelectrical impedance (TANITA sc-330; 156 
Tanita corporation). All measurements were obtained with the subjects in underwear 157 
and after an overnight fast. Anthropometric and body composition measurements were 158 
performed according to previously described standardized procedures [29]. 159 
 160 
Hormonal and biochemical analyses 161 
Venous blood samples were drawn after a 12-h overnight fast at the beginning of 162 
the restriction diet (pre-intervention, wk 0), the end of the diet intervention (post-163 
intervention, wk 8), and 4 months after the self-control period (follow-up, wk 24). 164 
Blood samples from normal-weight subjects were obtained under basal conditions after 165 
an overnight fast. EDTA-plasma and serum of specimens were separated from whole 166 
blood and immediately frozen at -80º C until assay. 167 
The quantitative measurement of betatrophin in human plasma samples was 168 
analyzed using a commercial enzyme-linked immunosorbent assay (ELISA) kit 169 
(Phoenix Pharmaceuticals, Inc., CA), according to the manufacturer’s instructions. 170 
Absorbance from each sample was measured in duplicate using a spectrophotometric 171 
microplate reader at a wavelength of 450 nm (Versamax Microplate Reader; Associates 172 
of Cape Cod Incorporated, East Falmouth, MA). 173 
Serum concentrations of glucose, total cholesterol (TC), triglycerides (TG), 174 
high-density lipoprotein cholesterol (HDL-c), homocysteine, free fatty acids (FFA), 175 
aspartate aminotransferase (AST) and aspartate aminotransferase (AST) were measured 176 
using an autoanalyzer (Pentra C-200; HORIBA ABX, Madrid, Spain) with specific kits. 177 
Low-density lipoprotein-cholesterol (LDL-c) levels were calculated using the 178 
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Friedewald formula [30]. Apolipoproteins AI and B were measured with specific kits 179 
(Tina-quant Apolipoprotein A-I ver.2 and Tina-quant Apolipoprotein B ver.2) with the 180 
help of an autoanalyzer (Roche/Hitachi model 904/911/912/917/ Modular: Roche 181 
Diagnostics).  182 
Overnight fasting plasma levels of ghrelin, leptin and adiponectin were 183 
measured using commercially available ELISA kits (Millipore, MA, USA). Plasma 184 
levels of irisin were measured using a commercial ELISA kit that was directed against 185 
amino acids 31-143, which includes the extracellular part of the FNDC5 protein (Irisin 186 
ELISA kit EK-067-52; Phoenix Pharmaceuticals, CA). Insulin concentrations were 187 
assessed using an ELISA kit from Mercodia, AB (Uppsala, Sweden). Insulin resistance 188 
was indirectly determined using the homeostatic model assessment index (HOMA-IR), 189 
which was calculated as follows: [fasting plasma glucose (mM) x fasting plasma insulin 190 
(μU/mL)/22.5], as described previously [31].  191 
 192 
Statistical analysis 193 
The sample size of the current trial was calculated to detect differences for 194 
betatrophin between obese and normal-weight patients taking into account published 195 
values of circulating betatrophin standard deviation [12]. It was calculated for an effect 196 
size ≥0.5 ng/mL, and α=0.05, and a power (1-β) of 80%. Thus, the sample size was 197 
established at a minimum of 15 volunteers per group to detect differences according to 198 
the adiposity levels. The sample size provided sufficient power to test for effects on a 199 
number of other metabolic variables of interest.  200 
The normal distribution of variables was explored using the Kolmogorov-201 
Smirnov and Shapiro-Wilk tests. An ANCOVA was used to study differences between 202 
groups adjusted for gender and age. A repeated-measures ANCOVA was used to study 203 
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the effects of time of the nutritional therapy program and groupings on body weight and 204 
biochemical parameters in obese patients adjusted for gender. The potential association 205 
between anthropometrical and biochemical parameters and betatrophin levels were 206 
evaluated using the Spearman coefficient test. 207 
The effects of high or low pre-intervention betatrophin levels on dietary-induced 208 
changes and the association between protein intake and post-treatment betatrophin 209 
levels were analyzed using the median (above and below the 50th percentile) cutoff 210 
values of betatrophin as previously applied [32] and based on a validated method to 211 
assign the studied population into two groups of disease risk [33].  212 
Multivariate linear regression models were fitted to assess the potential 213 
predictive factors of betatrophin levels after treatment and adjusted for age and gender. 214 
Three regression models were performed. Model 1 included variables for body 215 
composition and glucose and lipid metabolism-related parameters. Model 2 also 216 
included total protein and model 3 included animal protein intake.  217 
Statistical analysis was performed using SPSS version 17.0 software (SPSS Inc., 218 
Chicago, IL) for Windows XP (Microsoft, Redmond, WA). P ≤ 0.05 was considered 219 
statistically significant. 220 
 221 
RESULTS 222 
Circulating levels of betatrophin were evaluated in 143 subjects, including 48 normal-223 
weight and 95 metabolic syndrome patients of both genders, whose characteristics are 224 
shown in Supplementary Table 1. Circulating betatrophin concentrations were 225 
significantly higher in obese-metabolic syndrome subjects (1.24±0.06 ng/ml) than 226 
normal-weight subjects (0.97±0.08 ng/ml), and the difference was statistically 227 
significant (p=0.012) after adjusting for age and gender (Figure 1). Additionally, 228 
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although slightly low levels of betatrophin were observed in patients diagnosed with 229 
T2DM, the difference was not statistically significant (1.27±0.051 ng/ml vs. 1.13±0.08; 230 
p=0.180), neither when patients were classified according to the IDF criteria (1.25±0.08 231 
vs. 1.23±0.05; p=0.873) nor regarding the insulin resistance (1.30±0.08 vs 1.20±0.05; 232 
p=0.284) respect to the patients without these conditions. No gender-dependent 233 
component was detected when 66 men (1.18±0.08 ng/ml) and 76 women (1.10±0.06 234 
ng/ml) were compared (p=0.425), and no statistically significant interaction between 235 
metabolic syndrome and gender (p=0.182) was observed (Figure 1).  236 
Notably, circulating betatrophin levels in metabolic syndrome and normal-weight 237 
patients together were associated with several anthropometric and body composition 238 
measurements and biochemical variables related to lipid and glucose homeostasis 239 
(Table 1). Betatrophin positively correlated with body weight (r=0.24; p=0.004), BMI 240 
(r=0.30; p<0.001), waist circumference (r=0.23; p=0.014), fat mass (r=0.20; p=0.028) 241 
and fat-free mass (r=0.23; p=0.013) measured in kg. Betatrophin levels also directly 242 
associated with circulating levels of glucose (r=0.32; p<0.001), insulin (r=0.27; 243 
p=0.001), HOMA (r=0.28; p=0.001) and triglycerides (r=0.18; p=0.028). Leptin 244 
(r=0.24; p=0.012) and irisin (r=0.33; p<0.001) levels directly correlated with 245 
betatrophin. 246 
In the obese-metabolic syndrome patients, the nutritional treatment induced a 247 
statistically significant weight loss over 8 weeks (-6.73±0.71 kg and -7.09± 0.82 kg in 248 
the AHA and RESMENA groups, respectively) and a reduction in BMI, waist 249 
circumference, body fat mass and biochemical variables without differences between 250 
the dietary groups. Therefore, the obese-metabolic syndrome patients were merged and 251 
distributed into two groups according to the median pre-intervention values of 252 
betatrophin (1.21 ng/ml). Patients with pre-intervention (wk 0) betatrophin levels higher 253 
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than 1.21 ng/ml exhibited a lower decrease in fat mass percent (-2.36±0.45% vs. -254 
3.38±0.30%; p=0.024) and greater diminution in fat-free mass (-2.09±0.43 kg vs. -255 
1.03±0.30 kg; p=0.049) than patients with pre-intervention betatrophin levels lower than 256 
1.21 ng/ml (Table 2). Notably, the diet-induced diminution in HDL was more severe in 257 
patients with pre-intervention betatrophin levels that were higher than the median. This 258 
finding was also evidenced in the atherogenic index TG/HDL (Table 2). In fact, pre-259 
intervention betatrophin levels were associated with diet-induced changes in body fat 260 
mass (r=0.23; p=0.024), HDL levels (r=-0.33; p=0.001) and the TG/HDL index (r=0.25, 261 
p=0.016; Figure 2A-C), which indicates that greatest diet-induced benefit on 262 
atherogenic risk factors was achieved in patients with the lowest circulating betatrophin 263 
levels. No association was found between pre-intervention betatrophin levels and 264 
changes in glucose homeostasis factors, such as glucose, insulin and HOMA (Table 2).   265 
Evaluations of the circulating betatrophin levels in all patients together following the 266 
nutritional treatment (Figure 3A) revealed no statistically significant differences 267 
(p=0.208) after the energy restriction (wk0: 1.25±0.05 ng/ml; wk8: 1.19±0.053 ng/ml) 268 
and subsequent follow-up (wk24: 1.25±0.053) period. However, the AHA group 269 
exhibited higher betatrophin levels than the RESMENA group after the intervention 270 
period (wk8) and follow-up period (wk24) (Figure 3A). These differences were 271 
statistically significant (p<0.05; Figure 3A). When the interaction diet x baseline 272 
betatrophin levels was examined in post-intervention betarophin levels, this interaction 273 
was not statistically significant (diet x baseline betatrophin levels interaction p-274 
value=0.979). These results reveal an effect of the composition of the diet rather than 275 
the energy-restriction. 276 
Then, the associations between betatrophin levels and protein intake after treatment 277 
were evaluated because the relevant difference between the dietary regimens included a 278 
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higher total protein intake in the RESMENA group [28]. Accordingly, patients who 279 
consumed a total protein intake below the median value (67.1 g/day) exhibited 280 
statistically significant higher betatrophin levels than patients who reported a daily total 281 
protein intake higher than 67.1 g/d after the intervention and follow-up period (Figure 282 
3B). No statistically significant differences were detected in the daily intake of 283 
vegetable protein at wk8 and wk 24 (Figure 3C), but differences were observed for the 284 
daily intake of animal protein (p<0.05) (Figure 3D). Linear regression models revealed 285 
that 20% of the variability in post-treatment betatrophin levels was conjointly explained 286 
by the dietary-induced changes in body composition, lipid profile and animal-based 287 
protein intake within the hypocaloric diet (Table 3).  288 
 289 
DISCUSSION 290 
Metabolic syndrome prevalence has increased rapidly in the past two decades, which 291 
highlights the necessity for the development of effective therapeutic approaches [34]. 292 
Betatrophin, which is also named lipasin or ANGPTL8, is a protein that is encoded by 293 
the GM6484 gene in mice and C19orf80 in humans. Betatrophin is predominantly 294 
expressed in the human liver, and it is involved in the regulation of lipid metabolism. 295 
Betatrophin provides new hope for the treatment of hyperlipidemia, type 2 diabetes, 296 
obesity and related metabolic disorders [34].  297 
The present study demonstrated high levels of ANGPTL8/betatrophin/lipasin in 298 
metabolic syndrome patients, and the circulating levels of this protein positively 299 
associated with anthropometric and body composition measures, circulating levels of 300 
glucose, insulin, HOMA-IR and triglycerides, and hormones, such as leptin and irisin. 301 
Notably, patients with low levels of pre-intervention betatrophin experienced better 302 
beneficial effects of the weight loss program on atherogenic, but not glucose 303 
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intolerance, risk factors than patients with high levels of betatrophin. Circulating levels 304 
of betatrophin did not vary following the energy-restricted weight-loss treatment in 305 
obese-metabolic syndrome patients despite the association between betatrophin and 306 
body composition measures. However, the dependence of betatrophin levels on total 307 
dietary protein intake, with circulating betatrophin levels being higher in patients with 308 
lower protein intake, was observed for the first time. This association was particularly 309 
evident after the intake of protein of animal origin but not after protein-derived from a 310 
vegetable source. 311 
Betatrophin/lipasin-null mice exhibit reduced serum triglycerides [12, 16, 35], but 312 
betatrophin overexpression dramatically increases serum triglycerides [12, 17]. 313 
Moreover, a single-nucleotide polymorphism in the betatrophin gene, a mutation with a 314 
putative loss-of-function, is associated with an improved lipid profile in genome-wide 315 
association studies [14, 23]. Previous studies in humans revealed high levels of 316 
betatrophin in obesity and type 2 diabetes [12, 18-22] and a positive correlation between 317 
circulating betatrophin levels and serum lipid levels [23]. These observations are also 318 
consistent with our results in subjects with metabolic syndrome features. In contrast, a 319 
recent study concluded that serum betatrophin is decreased in human obesity, and this 320 
study reported an inverse association between betatrophin levels and obesity-associated 321 
cardiometabolic risk factors [25]. These differences may be due to methodological 322 
differences, including the use of different inmunoassays that detect different fragments 323 
(the N- and C-terminal kits) of betatrophin [36]. However, these discrepancies may also 324 
be due to disparities in the patients included in the studies. Our study included 325 
overweight and obese patients with metabolic syndrome and no statistical differences in 326 
betatrophin were observed in spite of high glucose profile and insulin resistance 327 
presence. Similar findings were recently reported [24]. These results and the data here 328 
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reported highlight the relevance of fat mass on the regulation of the betatrophin 329 
circulating levels rather than the altered carbohydrate metabolism. Therefore, it could be 330 
postulated that betatrophin is secreted as an adaptive response in overweight and 331 
moderately obese metabolic syndrome patients to counteract the lipid and glucose 332 
metabolism disorders that are associated with metabolic syndrome. This response of 333 
betatrophin secretion could be dramatically disturbed and/or downregulated in high-risk 334 
populations, such as morbid obese patients.  335 
The findings observed in the current nutritional intervention study of metabolic 336 
syndrome patients support this hypothesis. Patient categorization according to 337 
betatrophin levels before the beginning of the nutritional treatment revealed that patients 338 
with lower betatrophin levels exhibited better improvements in body fat mass and 339 
atherogenic variables induced by the energy restriction treatment. This outcome 340 
suggests that patients with low circulating betatrophin levels are in a more favorable 341 
obesity-related state to achieve a greater effect of the energy restriction treatment in the 342 
short-term than patients with high circulating betatrophin levels prior to therapeutic 343 
intervention.  344 
Importantly, the betatrophin levels did not vary following the energy restriction 345 
treatment in spite of their association with body fat mass but differences were observed 346 
depending on the assigned diet. The RESMENA diet in the current study differs from 347 
the AHA diet because the former diet was designed to obtain 30% of energy from 348 
proteins, and the AHA diet was designed to obtain only 15% of energy from proteins. 349 
Patients following the RESMENA diet recorded higher protein intake than patients who 350 
followed the AHA diet, and RESMENA patients exhibited a reduction in android fat 351 
mass values, which is a marker of central obesity that is associated with increased risk 352 
of metabolic syndrome manifestations [28], consistent with previous reports [37-39]. 353 
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The current study demonstrated for the first time an inverse association between 354 
circulating betatrophin levels and protein intake within a hypocaloric diet. 355 
Paradoxically, this association was particularly marked with protein derived from 356 
animal sources because patients with higher animal protein intake showed lower 357 
betatrophin levels.  358 
Protein derived from animal sources was associated with increased risks of global and 359 
abdominal obesity in healthy adults, which suggests that a lower animal protein intake 360 
is important for the maintenance of healthy body weight [40]. In contrast, vegetable 361 
protein intake appears to play a role in preventing obesity in European adolescents, 362 
which was observed in the HELENA cross-sectional study [41]. Moreover, a higher 363 
intake of animal protein, which was recorded in the RESMENA diet group [42] and the 364 
DiOGenes project [43], was associated with higher plasma levels of inflammatory 365 
markers in obese adults.   366 
The RESMENA diet group also recorded higher antioxidant capacity (TAC) of the diet 367 
and a beneficial effect on oxidative stress markers than the AHA diet [28]. However, no 368 
association was observed in the current study between betatrophin levels and the TAC 369 
of the diet, oxidative stress, or circulating inflammatory markers (data not shown), 370 
which suggests that protein intake is the most relevant dietary factor in betatrophin 371 
regulation. In fact, the regression model evidenced that protein intake within an energy-372 
restricted treatment, conjointly with the induced changes in body composition and lipid 373 
profile, determined betatrophin levels after the nutritional intervention (post-374 
intervention).  375 
The strength of this study is its longitudinal design which allows for the first time the 376 
evaluation of the time-course of changes of betathrophin as well as its association with 377 
the response to a weight-lowering treatment in obese patients. Meanwhile, because this 378 
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report describes an observational association study, this work is not able to demonstrate 379 
causality. The interplay between betatrophin levels and protein intake, quantity and 380 
quality, should be further explored in pre-clinical and clinical studies. 381 
In conclusion, the current results demonstrate that betatrophin levels are increased in 382 
overweight and moderately obese patients with metabolic syndrome features and 383 
positively associated with adiposity, lipid metabolism and glucose homeostasis 384 
parameters. Notably, the current work demonstrates for the first time that lower baseline 385 
circulating betatrophin levels are associated with a higher efficacy of a dietary weight-386 
reducing program in improving adiposity and dyslipidemia in obese patients with 387 
metabolic syndrome features. Moreover, the betatrophin concentration does not vary 388 
following the energy restriction treatment, but the levels are determined by the 389 
composition of the hypocaloric diet such as the content in animal-derived protein intake.  390 
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Figure legends 537 
Figure 1. Comparison of circulating betatrophin levels according to adiposity. 538 
Betatrophin levels were higher in obese-metabolic syndrome patients than normal 539 
weight-healthy patients. The data are presented as the means (SE). *Significant 540 
differences (p<0.05) between normal-weight and metabolic syndrome patients evaluated 541 
using ANCOVA adjusted by age and gender. 542 
 543 
Figure 2. Association between plasma betatrophin and diet-induced changes in percent 544 
body fat mass (A), circulating HDL levels (B), and the atherogenic index TG/HDL (C). 545 
HDL, high-density lipoprotein; TG, triglycerides. 546 
 547 
Figure 3. (A) Plasma betatrophin levels during the nutritional treatment (weeks 0-8) and 548 
the 4-month follow-up period (week 24). Data are presented as the means (SE). 549 
*Statistically significant differences (p<0.05) between the AHA and RESMENA diet 550 
groups. (B-C) Comparison of betatrophin levels after energy restriction treatment with 551 
regard to the protein intake. * Significantly different (p<0.05) compared to low protein 552 
intake. 553 
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Table 1. Association between baseline betatrophin circulating levels 
and anthropometric and biochemical parameters in normal weight 
and metabolic syndrome patients (n=143) 
  Spearman´s r coeficient p-value 
Age (years) 0.133 0.116 
Body weigt (kg) 0.244 0.004 
BMI (kg/m
2
) 0.303 <0.001 
Waist circumference (cm) 0.227 0.014 
Fat mass (%) -0.010 0.912 
Fat mass (kg) 0.200 0.028 
Fat-free mass (%) -0.114 0.216 
Fat-free mass (kg) 0.226 0.013 
Glucose (mg/dL) 0.316 0.000 
Insulin (mU/L) 0.273 0.001 
HOMA-IR 0.280 0.001 
Total Cholesterol (mg/dL) 0.045 0.599 
HDL-c (mg/dL) -0.071 0.408 
Triglycerides (mg/dL) 0.185 0.028 
Leptin (ng/mL) 0.241 0.012 
Irisin (ng/mL) 0.333 <0.001 
 
Table 2. Anthropometric and biochemical changes induced by the nutritional intervention according to pre-intervention (baseline) betatrophin circulating levels. 
 
Pre-intervention betatrophin lower levels  
(<1.21 ng/ml; n=47) Difference    
Pre-intervention betatrophin higher levels 
 (≥1.21 ng/ml; n=48) Difference  Difference 
P value Pre-intervention (wk0)  
Post-intervention 
(wk8) 
 
P value 
 
 
Pre-intervention 
(wk0)  
Post-intervention 
(wk8) P value 
Mean SD  Mean SD Mean SD  Mean SD  Mean SD Mean SD 
Body weight (kg) 99.2 15.3  92.3 14.2 0.000 -6.8 2.9   99.9 20.1  92.9 19.7 0.000 -6.9 3.1 0.856 
BMI (kg/m2) 35.3 4.5  32.9 4.2 0.000 -2.4 1.0  36.3 4.8  33.7 4.9 0.000 -2.5 1.1 0.687 
Waist circumference (cm) 110.5 12.4 103.6 11.1 0.000 -6.9 4.7 111.4 13.2 104.0 12.7 0.000 -7.4 4.2 0.576 
Fat mass (%) 39.0 7.4  35.7 7.7 0.000 -3.4 2.1  39.3 6.7  36.9 7.1 0.000 -2.4 3.1 0.024 
Free-fat mass (kg) 60.4 11.8  59.4 11.5 0.002 -1.0 2.1  60.6 13.8  58.5 13.3 0.000 -2.1 3.0 0.049 
SBP (mmHg) 144.7 16.6  135.8 14.0 0.000 -8.9 14.8  153.1 20.5  138.0 18.7 0.000 -15.2 22.0 0.105 
DBP (mmHg) 83.9 9.2  76.9 9.1 0.000 -7.0 7.4  85.5 9.1  79.0 10.0 0.000 -6.4 11.34 0.776 
TC (mg/dL) 212.4 41.9  199.5 41.7 0.054 -12.9 44.2  225.9 43.3  208.2 43.1 0.001 -17.7 32.9 0.556 
LDL-c (mg/D) 133.5 38.4  131.7 36.8 0.766 -1.8 40.9  141.6 37.9  133.7 37.6 0.036 -7.9 25.2 0.388 
HDL-c (mg/dL) 42.6 9.3  41.5 8.8 0.281 -1.0 6.4  46.7 10.1  42.1 9.6 0.000 -4.6 7.2 0.013 
TG/HDL-c (mg/dL) 0.58 0.27  0.47 0.23 0.000 -0.11 0.19  0.55 0.30  0.52 0.30 0.395 -0.02 0.17 0.020 
TC/HDL-c (mg/dL) 5.1 1.2  4.9 1.1 0.195 -0.21 1.1  5.0 1.1  5.1 1.1 0.338 0.11 0.79 0.105 
LDL/HDL-c (mg/dL) 3.2 0.8  3.2 0.91 0.729 0.05 1.0  3.1 0.75  3.2 0.80 0.127 0.15 0.66 0.555 
ApoA1 (mg/dL) 129.0 18.4  119.6 18.2 0.000 -9.5 11.4  138.5 23.8  125.2 21.2 0.000 -13.2 16.2 0.199 
ApoB (mg/dL) 90.8 22.4  81.4 20.2 0.000 -9.4 16.2  101.3 22.9  92.3 22.3 0.000 -9.0 13.6 0.878 
Glucose (mg/dL) 123.3 38.2  108.7 21.5 0.009 -14.5 36.1  122.0 34.1  108.3 19.3 0.005 -13.6 31.6 0.894 
Insulin ( mU/L) 14.5 7.87 8.6 4.9 0.000 -5.9 5.3 14.9 11.6 9.6 7.8 0.000 -5.2 7.3 0.608 
HOMA-IR 4.5 2.8  2.4 1.6 0.000 -2.1 1.9  4.6 3.9  2.7 2.5 0.000 -1.9 2.6 0.730 
TG (mg/dL) 181.8 106.5  131.4 62.1 0.000 -50.4 82.0  187.6 112.0  162.0 102.7 0.012 -25.7 67.4 0.115 
Homocisteine (μmol/L)    15.1 3.9  15.9 4.0 0.139 0.8 3.5  15.9 3.5  15.1 3.2 0.075 0.77 2.9 0.978 
FFA (mg/dL) 0.53 0.19  0.53 0.26 0.929 0.00 0.26  0.56 0.21  0.48 0.19 0.011 -0.08 0.21 0.122 
ALT (U/L) 32.1 14.1  29.9 13.4 0.320 -2.3 15.2  34.6 20.2  26.6 11.8 0.002 -8.1 16.9 0.084 
AST (U/L) 23.9 8.9  22.3 6.1 0.200 -1.6 8.1  23.8 9.0  20.3 5.7 0.007 -3.5 8.6 0.256 
Irisin (ng/mL) 345.7 201.9  266.3 122.7 0.000 -79.4 124.1  363.4 156.9  299.0 123.9 0.000 -64.4 81.2 0.491 
Leptin (ng/mL) 20.4 17.6  12.4 11.7 0.000 -7.9 10.0  22.4 11.7  15.3 10.6 0.000 -7.1 8.6 0.669 
Adiponectin (ng/mL) 10.8 7.9  14.5 17.8 0.191 3.7 18.8  15.1 11.0  17.2 17.5 0.418 2.1 17.6 0.676 
Ghrelin (pg/mL) 431.5 265.7  526.5 318.8 0.003 95.1 163.4   371.7 117.4  418.4 142.4 0.024 46.6 116.4 0.167 
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FIGURE 3 
Post-intervention 
Table 3. Independent effects of dietary-induced changes (Δ=wk8-wk0)  in body composition, biochemical 
parameters and protein intake on circulating betatrophin levels after nutritional intervention (post-intervention)
Model 1 
Standardized 
coefficients B 95%CI P-value
Δ Fat mass (kg) 0.419 0.025 0.093 0.001 
Δ Fat-free mass (kg) 0.227 -0.006 0.091 0.082 
Δ Fasting LDL_c (mg/dL) -0.313 -0.007 -0.001 0.005 
Δ Fasting HDL_c (mg/dL) 0.146 -0.005 0.025 0.173 
Δ Fasting glucose (mg/dL) -0.153 -0.005 0.001 0.150 
Δ Fasting insulin (U/mL) -0.060 -0.021 0.012 0.562 
Corrected R2 = 0.12 0.008 
Model 2 
Δ Fat mass (kg) 0.440 0.030 0.102 0.000 
Δ Fat-free mass (kg) 0.207 -0.009 0.090 0.107 
Δ Fasting LDL_c (mg/dL) -0.330 -0.008 -0.002 0.004 
Δ Fasting HDL_c (mg/dL) 0.217 -0.001 0.031 0.058 
Δ Fasting glucose (mg/dL) -0.129 -0.005 0.001 0.233 
Δ Fasting insulin (U/mL) -0.063 -0.022 0.012 0.549 
Post-intervention total protein intake (g/d) -0.203 -0.011 0.000 0.060 
Corrected R2 = 0.16 0.004 
Model 3 
Δ Fat mass (kg) 0.481 0.037 0.109 0.000 
Δ Fat-free mass (kg) 0.236 -0.003 0.096 0.066 
Δ Fasting LDL_c (mg/dL) -0.351 -0.008 -0.002 0.002 
Δ Fasting HDL_c (mg/dL) 0.221 0.000 0.031 0.046 
Δ Fasting glucose (mg/dL) -0.114 -0.005 0.001 0.286 
Δ Fasting insulin (U/mL) -0.079 -0.023 0.010 0.444 
Post-intervention animal protein intake (g/d) -0.267 -0.013 -0.002 0.012 
Corrected R2 = 0.20       0.001 
 
